HUM has now cleared its July 29 earnings hurdle, and the data is updating in real time — the defensive options signal that dominated the pre-earnings note has partially unwound, but short interest has begun creeping back and the Street remains split on where the stock goes next.
The most notable shift since the earnings preview is in short positioning. SI ticked up 10% on the week to 3.46% of free float — reversing a brief dip — after collapsing from roughly 6% in mid-June to a trough near 3.2%. That's a modest rebuilding, not a crowding event, but the direction has changed. Cost to borrow tells the opposite story: it has eased sharply, down 23% on the week to just 0.31%, the lowest level in the 30-day window. Borrow availability is extraordinarily loose at roughly 9,565% — meaning shares available to borrow dwarf what is currently borrowed — so there is no friction for new shorts to establish positions if they choose to. Together, the signals describe a market where bears are quietly adding exposure back at low cost, with plenty of room to grow if sentiment sours.
Options positioning has also pulled back from the extreme reading flagged in the pre-earnings note. The put/call ratio closed at 1.00 on July 28, still above its 20-day mean of 0.94 but the z-score has dropped to 1.93 from the near-2.8 reading seen heading into the print. That is still modestly defensive — puts outnumber calls — but the acute hedging demand ahead of the event has faded. The ratio has been grinding higher for most of July, rising from a base around 0.91–0.93 in early July; it's not alarming, but it's not call-led either.
The Street's reaction to the earnings print will sharpen the analyst picture considerably. Ahead of the result, the analyst cluster was mixed but trending constructively on price targets even as ratings stayed cautious: Wells Fargo upgraded to Overweight with a $502 target on July 13, while TD Cowen and Truist both raised targets to $350 and $415 respectively while holding at Hold. The consensus sits at Hold with nine buys against fourteen holds, and the mean price target of $352 is currently below the stock's $388.71 close — an unusual configuration that suggests the target-raising cycle hasn't fully caught up to the recent 48% year-to-date move. The bull case rests on Medicare Advantage margin recovery — the 500-basis-point improvement in Group MA margins — while the bear case centres on the estimated $3.5 billion Star ratings headwind and a potential $22 EPS drag in 2026. EPS momentum factor scores rank in the 90th percentile on both 30-day and 90-day windows, a strong read, but the analyst recommendation divergence score at the 94th percentile captures just how wide the gap between bulls and bears has grown.
Among peers, the picture is also mixed post-week. CI gained 3.6% on the week and was the standout outperformer in the managed care group. CVS and UNH both slipped around 1–1.7%, broadly in line with HUM's 3.9% weekly decline. CNC fared worse, down 5.4%, and ASTH dropped 16.5% — making HUM's pullback look contained by comparison within the sector's choppy week.
With earnings now in the rearview, the focus shifts to management commentary on Star ratings remediation and any guidance revision on 2026 margins — that is where the $352 consensus target versus a ~$389 stock price will get stress-tested or validated.
See the live data behind this article on ORTEX.
Open HUM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
